Cite
HARVARD Citation
Sharrack, B. et al. (2022). 019 Autologous stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis (StarMS). Journal of neurology, neurosurgery and psychiatry. 93 (6), p. A19. [Online].